Home » India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

November 16, 2016

Pharmaceuticals Regulatory Affairs

India is giving drugmakers of unapproved combination products more time to justify their manufacturing and marketing of the drug in the country.

To View This Article:

Login

30Nov
The Unification Impact: The Unique Benefits of One System that Replaces Many
01Dec
Engaging with the FDA: Best Practices for Dealing with Warning Letters, Seizures, Injunctions — and More
08Dec
2022 Year in Review: The Future of Clinical Research Sites Series Finale & Look to 2023
13Dec
Building a World-Class Regulatory Intelligence and Support System: What Regulatory, Compliance and Quality Professionals Need to Know
14Dec
Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements